Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(O)C1=CC=C(O)C=C1
InChI
InChIKey=YRCWQPVGYLYSOX-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-2-4-8(11)5-3-7/h2-5,9-12H,6H2,1H3
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21904645Curator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/oxedrine.html | https://clinicaltrials.gov/ct2/show/NCT01423019 | https://www.ncbi.nlm.nih.gov/pubmed/20217639
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21904645
Curator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/oxedrine.html | https://clinicaltrials.gov/ct2/show/NCT01423019 | https://www.ncbi.nlm.nih.gov/pubmed/20217639
Oxedrine (Sympatol, p-synephrine) is a naturally occurring alkaloid molecule first appeared in Europe towards the end of the 1920s being sold as a drug under the brand name Sympatol. Oxedrine was then being prescribed as a remedy for a number of respiratory conditions, which include asthma, whooping cough, colds, and hay fever. More recently, synephrine gained popularity as a weight loss aid and it has become a favored component in the more popular brands of weight loss supplement stacks. This popularity can be attributed in part to the ban imposed on ephedra, to which it shares similar mechanisms of action. Most, if not all of the synephrine being sold as a dietary supplement is extracted and synthesized from the Citrus aurantium plant, more commonly known as bitter orange. Just like ephedrine, synephrine has vasoconstrictive abilities, although at a lesser potency compared to ephedrine. There is no mention of synephrine in editions of Drill's Pharmacology in Medicine later than the 3rd, nor is there any reference to synephrine in the 2012 Physicians' Desk Reference, nor in the current FDA "Orange Book". One current reference source describes synephrine as a vasoconstrictor that has been given to hypotensive patients, orally or by injection, in doses of 20–100 mg.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25262941 |
6.6 µM [EC50] | ||
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20217639 |
4.11 null [pKi] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20217639 |
4.44 null [pKi] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20217639 |
4.61 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Advantra Z Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.86 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
427.9 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
466.4 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341680/ |
21 mg single, oral dose: 21 mg route of administration: Oral experiment type: SINGLE co-administered: CAFFEINE |
OXEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg single, oral Studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: Page: p.5 |
healthy, 22.3 ± 1.6 n = 12 Health Status: healthy Age Group: 22.3 ± 1.6 Sex: M Population Size: 12 Sources: Page: p.5 |
|
100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: caffeine, p.o(400 mg, q.d, 2 weeks) Sources: Page: p.11 |
healthy, 27 n = 1 Health Status: healthy Age Group: 27 Sex: F Population Size: 1 Sources: Page: p.11 |
Disc. AE: Ventricular fibrillation... AEs leading to discontinuation/dose reduction: Ventricular fibrillation Sources: Page: p.11 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ventricular fibrillation | Disc. AE | 100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: caffeine, p.o(400 mg, q.d, 2 weeks) Sources: Page: p.11 |
healthy, 27 n = 1 Health Status: healthy Age Group: 27 Sex: F Population Size: 1 Sources: Page: p.11 |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous quantification of adrenergic amines and flavonoids in C. aurantium, various Citrus species, and dietary supplements by liquid chromatography. | 2005 Nov-Dec |
|
Analysis of ephedra-free labeled dietary supplements sold in the San Francisco Bay area in 2003. | 2006 |
|
Response of CEDIA amphetamines assay after a single dose of bitter orange. | 2006 Apr |
|
Variant angina associated with bitter orange in a dietary supplement. | 2006 Apr |
|
Metal content of ephedra-containing dietary supplements and select botanicals. | 2006 Apr 1 |
|
Abnormal platelet trace amine profiles in migraine with and without aura. | 2006 Aug |
|
Reporting associations between dietary supplements and adverse events. | 2006 Dec |
|
A rapid and simple procedure for the determination of synephrine in dietary supplements by gas chromatography-mass spectrometry. | 2006 Jun 16 |
|
Thermogenic effect from nutritionally enriched coffee consumption. | 2006 Jun 5 |
|
Development and validation of HPLC methods for the analysis of phenethylamine and indoloquinazoline alkaloids in Evodia species. | 2006 Mar |
|
Chemical and biological comparisons on Evodia with two related species of different locations and conditions. | 2006 Nov 24 |
|
Consumption of dietary supplements containing Citrus aurantium (bitter orange)--2004 California Behavioral Risk Factor Surveillance Survey (BRFSS). | 2006 Oct |
|
[Determination of three chemical components in Fructus aurantii immaturus]. | 2006 Sep |
|
Strategies for enantioseparations of catecholamines and structurally related compounds by capillary zone electrophoresis using sulfated beta-cyclodextrins as chiral selectors. | 2006 Sep |
|
Determination of octopamine, synephrine and tyramine in Citrus herbs by ionic liquid improved 'green' chromatography. | 2006 Sep 1 |
|
Evaluation of the stimulant content of dietary supplements marketed as "ephedra-free". | 2007 |
|
Influence of microemulsion chirality on chromatographic figures of merit in EKC: results with novel three-chiral-component microemulsions and comparison with one- and two-chiral-component microemulsions. | 2007 Aug |
|
Two-chiral component microemulsion EKC - chiral surfactant and chiral oil. Part 2: diethyl tartrate. | 2007 Aug |
|
Chromatographic and electrophoretic methods for the analysis of phenethylamine [corrected] alkaloids in Citrus aurantium. | 2007 Aug 17 |
|
Lipolysis induced by segment wall extract from Satsuma mandarin orange (Citrus unshu Mark). | 2007 Dec |
|
Trace amine-associated receptor 1-Family archetype or iconoclast? | 2007 Dec |
|
Effects of ingesting JavaFit Energy Extreme functional coffee on aerobic and anaerobic fitness markers in recreationally-active coffee consumers. | 2007 Dec 8 |
|
Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization. | 2007 Feb |
|
Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. | 2007 Jan 26 |
|
Determination of synephrine in bitter orange raw materials, extracts, and dietary supplements by liquid chromatography with ultraviolet detection: single-laboratory validation. | 2007 Jan-Feb |
|
Determination of Bitter Orange alkaloids in dietary supplements standard reference materials by liquid chromatography with ultraviolet absorbance and fluorescence detection. | 2007 Jul 13 |
|
A case of severe exercise-induced rhabdomyolysis associated with a weight-loss dietary supplement. | 2007 Jun |
|
Two-chiral-component microemulsion electrokinetic chromatography-chiral surfactant and chiral oil: part 1. dibutyl tartrate. | 2007 Jun |
|
Determination of synephrine in weight-loss products using high performance liquid chromatography with acidic potassium permanganate chemiluminescence detection. | 2007 Jun 12 |
|
Chemiluminescence of synephrine based on the cerium(IV)-rhodamine B system. | 2007 Mar-Apr |
|
Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism. | 2007 May |
|
Simultaneous analysis of adrenergic amines and flavonoids in citrus peel jams and fruit juices by liquid chromatography: part 2. | 2007 May-Jun |
|
Mass spectrometric determination of the predominant adrenergic protoalkaloids in bitter orange (Citrus aurantium). | 2007 Nov 28 |
|
Temperature effects on the enantioselectivity of basic analytes in capillary EKC using sulfated beta-CDs as chiral selectors. | 2007 Oct |
|
Simultaneous determination of flavonoid and alkaloid compounds in Citrus herbs by high-performance liquid chromatography-photodiode array detection-electrospray mass spectrometry. | 2007 Oct 1 |
|
Determination of bitter orange alkaloids in dietary supplement Standard Reference Materials by liquid chromatography with atmospheric-pressure ionization mass spectrometry. | 2007 Sep |
|
Fast high-performance liquid chromatography analysis of phenethylamine alkaloids in Citrus natural products on a pentafluorophenylpropyl stationary phase. | 2007 Sep 21 |
|
In vitro anticholinesterase activity of various alkaloids. | 2007 Sep-Oct |
|
Concentrations of p-synephrine in fruits and leaves of Citrus species (Rutaceae) and the acute toxicity testing of Citrus aurantium extract and p-synephrine. | 2008 Aug |
|
Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. | 2008 Dec 14 |
|
Citrus aurantium--beware of the bitter orange. | 2008 Jul |
|
Vasospasm and stroke attributable to ephedra-free xenadrine: case report. | 2008 Jul |
|
Sensitive determination of norepinephrine, synephrine, and isoproterenol by capillary electrophoresis with indirect electrochemiluminescence detection. | 2008 Jul |
|
Certification of standard reference materials containing bitter orange. | 2008 Jul |
|
Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions. | 2008 Jun |
|
Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine. | 2008 May |
|
Synephrine content of juice from Satsuma mandarins (Citrus unshiu Marcovitch). | 2008 Oct 8 |
|
Determination of ephedrine alkaloids in Ephedra natural products using HPLC on a pentafluorophenylpropyl stationary phase. | 2008 Sep 29 |
|
Screening for in vivo (anti)estrogenic activity of ephedrine and p-synephrine and their natural sources Ephedra sinica Stapf. (Ephedraceae) and Citrus aurantium L. (Rutaceae) in rats. | 2009 Jan |
|
Selectivity and potential interference from phenolic compounds in chemiluminescence methods for the determination of synephrine. | 2009 Mar-Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01423019
Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20217639
HEK293 cells stably expressing the α1A-AR were transfected with the TRE‑LUC plasmid (40 μg/mL) using electroporation (70msec, single pulse, 150 volts). The transfected cells were seeded at a density of 50000 cells/well in microtiter plates (Cultureplate®; Packard) in 200 μL media and allowed to grow for 24 h with incubation at 37°C (5% CO2). After 24 h, the cells were treated with various drug concentrations for 20 h, which was found to be optimum during time-course analyses performed earlier. When antagonist studies were performed, the compounds (Oxedrine 1nM-1mM) were added 15min prior to the addition of the agonist L-phenylephrine. Following drug exposures, the cells were lysed, and luciferase activity was measured using the Luclite assay kit
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 01:38:28 UTC 2022
by
admin
on
Sat Dec 17 01:38:28 UTC 2022
|
Record UNII |
PEG5DP7434
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01GA06
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-VATC |
QS01GA06
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-ATC |
S01GA56
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
DSLD |
2287 (Number of products:206)
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-VATC |
QC01CA08
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-ATC |
C01CA08
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-VATC |
QS01GA56
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
||
|
WHO-VATC |
QS01FB90
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7172
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
D013578
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
1642609
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
CHEMBL33720
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
SYNEPHRINE
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
M10412
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | Merck Index | ||
|
170956
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
10288
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | RxNorm | ||
|
29081
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
202-300-9
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
DTXSID0030588
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
SUB14726MIG
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
166285
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
94-07-5
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
DB09203
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
58606
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
PEG5DP7434
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY | |||
|
3577
Created by
admin on Sat Dec 17 01:38:28 UTC 2022 , Edited by admin on Sat Dec 17 01:38:28 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |